Wednesday, March 28, 2018

Singlera Genomics Finds $60M For Cancer Diagnosis

La Jolla-based Singlera Genomics, which is developing genetic diagnostics for early stage cancer detection, has raised $60M in a Series A+ funding round, according to the company. The funding was led Green Pine Capital Partners and Prosperico Ventures plus UCF Medical Investment, Jointown Pharmaceutical Group, and Lilly Asia Venture, as well as others. Singlera is split between La Jolla and Shanghai, China. The company said it is focusing on early stage detection of cancer using cell-free DNA. The company's initial target is early detection of lung cancer. Singlera said the new funding will go towards development and commercialization of its non-invasive, genetic tests plus for clinical validation studies, in addition to expansion of its research facilities and product lines. More information »